Direkt zum Inhalt
Merck

SML2268

Micafungin sodium

≥97% (HPLC), powder, β(1,3)-D-Glucan synthase inhibitor

Synonym(e):

1-[(4R,5R)-4,5-Dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]pneumocandin A0 sodium salt

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

5 MG

€ 90,70

25 MG

€ 369,00

€ 90,70


Warenkorb auf Verfügbarkeit prüfen

Großbestellung anfragen

Über diesen Artikel

Empirische Formel (Hill-System):
C56H70N9O23S · Na
CAS-Nummer:
Molekulargewicht:
1292.26
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:

Fortfahren mit

Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten

Produktname

Micafungin sodium, ≥97% (HPLC)

InChI

1S/C56H71N9O23S.Na/c1-4-5-6-16-86-32-9-7-8-29(17-32)39-21-33(63-87-39)27-10-12-28(13-11-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-14-15-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76;/h7-15,17-18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,16,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85);/q;+1/p-1/t25?,26-,31-,34+,35+,37-,38-,42?,43+,44?,45+,46+,47+,48+,52?;/m1./s1

SMILES string

O=C(N[C@H]1C[C@@H](O)[C@@H](O)NC([C@@H]2[C@@H](O)[C@@H](C)CN2C([C@H]([C@H](O)CC(N)=O)NC([C@@H](NC([C@]3([H])C[C@@H](O)CN3C([C@H]([C@H](O)C)NC1=O)=O)=O)[C@H](O)[C@H](C4=CC(OS(=O)([O-])=O)=C(O)C=C4)O)=O)=O)=O)C5=CC=C(C6=NOC(C7=CC=C(OCCCCC)C=C7)=C6)C=C5.[Na+

InChI key

DDVWCESGUGLBJI-OZMKZJPFSA-M

assay

≥97% (HPLC)

form

powder

storage condition

protect from light

color

white to beige

solubility

H2O: 2 mg/mL, clear (warmed)

shipped in

wet ice

storage temp.

−20°C

Verwandte Kategorien

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 4

Dieser Artikel
SML2288N2790SML1289
assay

≥97% (HPLC)

assay

≥97% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

form

powder

form

powder

form

powder

storage temp.

−20°C

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

2-8°C

storage condition

protect from light

storage condition

desiccated

storage condition

-

storage condition

-

solubility

H2O: 2 mg/mL, clear (warmed)

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: >15 mg/mL

solubility

H2O: 15 mg/mL, clear

color

white to beige

color

white to beige

color

yellow

color

faintly yellow to dark yellow

Application

Micafungin sodium has been used as an anti-fungal agent to test its effectiveness against multidrug-resistant C. auris by in vitro minimum inhibitory concentration (MIC) assay.

Biochem/physiol Actions

Micafungin is a semisynthetic echinocandin antifungal. Micafungin works by inhibiting the enzyme β(1,3)-D-Glucan synthase and thereby disturbing the integrity of the fungal cell wall. This enzyme does not exist in mammalian systems.
Micafungin is used for first-line treatment of invasive and esophageal candidiasis in addition to prophylaxis of Candida infections in both adults and children.
Semisynthetic echinocandin antifungal that inhibits 1,3-β-D-glucan synthase which is required for cell wall synthesis.

Lagerklasse

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

David Andes et al.
Antimicrobial agents and chemotherapy, 55(5), 2113-2121 (2011-02-09)
Echinocandins have become a first-line therapy for invasive candidiasis (IC). Using phase 3 trial data for patients with IC, pharmacokinetic-pharmacodynamic (PK-PD) relationships for efficacy for micafungin were examined. Micafungin exposures were estimated using a population pharmacokinetic model, and univariable and
David S Perlin
Future microbiology, 6(4), 441-457 (2011-04-30)
It has been nearly a decade since caspofungin was approved for clinical use as the first echinocandin class antifungal agent, followed by micafungin and anidulafungin. The echinocandin drugs target the fungal cell wall by inhibiting the synthesis of β-1,3-D-glucan, a
Roeland E Wasmann et al.
Clinical pharmacokinetics, 57(3), 267-286 (2017-08-10)
Micafungin is a selective inhibitor of the synthesis of fungal 1,3-β-D-glucan, an essential component of the fungal cell wall. It is available as a powder for infusion only and is registered for the treatment of invasive and esophageal candidiasis in
Giardia hinders growth by disrupting nutrient metabolism independent of inflammatory enteropathy.
Giallourou, et al.
Nature Communications, 14, 2840-2840 (2023)
G Kofla et al.
European journal of medical research, 16(4), 159-166 (2011-04-14)
Echinocandins represent the newest class of antifungal agents. Currently, three echinocandins, anidulafungin, caspofungin and micafungin are licensed for clinical use in various indications. They act as inhibitors of β-(1,3)-glucan synthesis in the fungal cell wall and have a favorable pharmacological

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung